The Use of infliximab in Treatment of Uveitis Associated with Behcet's disease | ||||
| International Journal of Health Sciences (Egypt) | ||||
| Volume 1, Issue 2, July 2023, Page 46-51 PDF (539.59 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ijhegy.2023.202225.1013 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Mortada Abozaid   1; Rana Nasser Saad-eldin2
| ||||
| 111 Othman Abozaid street from Algomhoreya street | ||||
| 2Department of Rheumatology and rehabilitation, Faculty of Medicine | ||||
| Abstract | ||||
| Purpose: to assess the safety and efficacy of infliximab in the treatment of uveitis associated with Behcet's disease. Methods: fifty patients with Behcet's related uveitis were included in this prospective comparative study. Cases were divided into 2 groups; group A(25 patients) received infliximab and group B (25 patients) received oral steroids. All cases were followed up to one year. Results: In group A, the mean BCVA (logMAR) improved from 0.48±0.14 at baseline to 0.07±0.12 three months after treatment. Also, the number of cases with grade 0 AC cells increased from 0 before starting treatment to 18 after 3 months. In group B, the mean BCVA (logMAR) improved from 0.47±0.13 at baseline to 0.17±0.15 three months after treatment. Also, the number of cases with grade 0 AC cells increased from 0 before starting treatment to 14 after 3 months. Conclusion: Infliximab is both safe and effective in treating uveitis associated with Behcet's disease. Studies with larger sample size and longer follow-up periods are needed to confirm the results. | ||||
| Keywords | ||||
| Anti-TNF; Behcet' s disease; Infliximab; Steroid sparing; Uveitis | ||||
|
Statistics Article View: 159 PDF Download: 122 |
||||
